DBP Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Teneligliptin | 760937-92-6 (free base) | sc-475074 | 25 mg | $260.00 | 1 | |
Teneligliptin inhibits DBP by competitively binding to its active site, obstructing the cleavage of dipeptides. This inhibition prolongs the action of incretin hormones, leading to enhanced insulin secretion and improved glucose utilization in diabetic conditions. | ||||||
Vildagliptin | 274901-16-5 | sc-208485 | 10 mg | $173.00 | 4 | |
Vildagliptin inhibits DBP activity by competitively blocking its active site, hindering the cleavage of dipeptides. This inhibition results in prolonged action of incretin hormones, leading to enhanced insulin secretion and improved glucose homeostasis. | ||||||
Sitagliptin | 486460-32-6 | sc-482298 sc-482298A sc-482298B | 25 mg 100 mg 1 g | $209.00 $464.00 $719.00 | 10 | |
Sitagliptin inhibits DBP by competitively binding to its active site, preventing the enzymatic cleavage of dipeptides. This inhibition leads to reduced breakdown of incretin hormones, ultimately resulting in increased insulin secretion and improved glycemic control. | ||||||
Saxagliptin | 361442-04-8 | sc-473161 | 1 mg | $360.00 | ||
Saxagliptin inhibits DBP by occupying its active site and obstructing substrate binding, thereby impeding the hydrolysis of dipeptides. This inhibition leads to elevated levels of intact incretin hormones, resulting in enhanced insulin secretion and improved glycemic control. | ||||||
Trelagliptin | 865759-25-7 | sc-507285 | 5 mg | $405.00 | ||
Trelagliptin inhibits DBP by binding to its active site, preventing the enzymatic hydrolysis of dipeptides. By interfering with DBP function, trelagliptin maintains elevated levels of circulating incretin hormones, leading to improved glucose-dependent insulin secretion and glycemic control. | ||||||
Linagliptin | 668270-12-0 | sc-364721 sc-364721A | 5 mg 10 mg | $255.00 $418.00 | 2 | |
Linagliptin inhibits DBP by forming a stable complex with the enzyme, blocking its catalytic activity. By directly interfering with DBP's function, linagliptin effectively suppresses the cleavage of dipeptides, thereby prolonging the action of incretin hormones and enhancing glucose-dependent insulin secretion. | ||||||
Anagliptin | 739366-20-2 | sc-507278 | 5 mg | $280.00 | ||
Alogliptin inhibits DBP by binding to its active site, preventing the enzyme from cleaving dipeptides. By competitively inhibiting DBP, alogliptin maintains higher levels of circulating incretin hormones, leading to increased insulin secretion and improved glucose metabolism. | ||||||
Gemigliptin tartrate | 1374639-74-3 | sc-507281 | 10 mg | $165.00 | ||
Gemigliptin inhibits DBP activity by forming a stable complex with the enzyme's active site, thereby preventing the hydrolysis of dipeptides. By blocking DBP function, gemigliptin maintains higher levels of circulating incretin hormones, promoting insulin secretion and glucose control. | ||||||
Omarigliptin | 1226781-44-7 | sc-507282 | 5 mg | $330.00 | ||
Omarigliptin inhibits DBP by competitively binding to its catalytic site, interfering with the cleavage of dipeptides. This inhibition results in elevated levels of intact incretin hormones, enhancing insulin secretion and improving glycemic regulation in diabetic individuals. | ||||||
Evogliptin | 1222102-29-5 | sc-507284 | 5 mg | $1060.00 | ||
Evogliptin inhibits DBP by forming a stable complex with the enzyme's active site, thereby preventing the cleavage of dipeptides. This inhibition leads to elevated levels of intact incretin hormones, promoting glucose-dependent insulin secretion and glycemic control in diabetic patients. | ||||||